Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patients

Abstract

Background Myasthenia gravis (MG) is an autoimmune disorder with fluctuating weakness that causes significant disability and morbidity. Comorbidities may influence the course of MG, particularly in specific subgroups. The aim of this study is to investigate the frequency of comorbidities in MG patients compared to healthy controls (HC) and to evaluate their distribution according to age at disease onset, sex, and disease severity. Methods MG patients attending the University Hospital “Paolo Giaccone” in Palermo and “SS Annunziata” Hospital in Chieti were enrolled; HC were enrolled from the general population. Non-parametric statistics and logistic regression were used to assess the association of specific comorbidities according to age at disease onset, sex, disease subtypes, and severity of the disease. Results A total of 356 subjects were included in the study: 178 MG patients (46% F; median age 60 years [51–71]) and 178 sex- and age-matched HC (46% F, median age 59 years [50–66]). Overall, 86% of MG patients and 76% of HC suffered from comorbidities, and MG patients had a higher number of comorbidities compared to HC. Patients with late-onset suffered from more comorbidities than those with early-onset MG. Hypertension was more common in male patients with MG, while thymic hyperplasia, osteoporosis, and autoimmune diseases were more common in females. Respiratory disorders and thymoma were more common in patients with more severe disease (p < 0.05 for all comparisons). Conclusion MG patients, particularly those with late onset, showed a higher prevalence of comorbidities than HC. Assessment of comorbidities in MG is an essential issue to identify the appropriate treatment and achieve the best management.

Real-World Case Series of Efgartigimod for Japanese Generalized Myasthenia Gravis: Well-Tailored Treatment Cycle Intervals Contribute to Sustained Symptom Control

“…In general, aging is correlated with a site-specific loss of skeletal muscle mass in both the extremities and trunk, and age-related loss of skeletal muscle mass and its function is also known as sarcopenia. Recent evidence has highlighted the impact of comorbidities on the management and outcome of MG [ 32 ]. Generalized EOMG in this study showed a more pronounced response to treatment with efgartigimod.…”